SCHEMBL4720346

SCHEMBL4720346

CCOc1ccccc1C1CCCC[N]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
HTR1D P28221 2/20 0.41
HTR1B P28222 2/20 0.41
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.39
ALOX12 P18054 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALOX15 P16050 1/20 0.39
BRCA1 P38398 1/20 0.39
HBB P68871 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 1/20 0.39
PTPRC P08575 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724844 0.95 HTR2A (0.46) ALDH1A1KDM4EHTR2AHTR2CHTR2B
SCHEMBL4720767 0.88 HTR1D (0.48) ALDH1A1KDM4EHTR2AHTR2CHTR2B
SCHEMBL4723202 0.87 HTR1D (0.49) ALDH1A1KDM4EHTR2CHTR2BHTR1D
SCHEMBL4721419 0.84 HTR2C (0.48) ALDH1A1KDM4EHTR2AHTR2CHTR2B
SCHEMBL4970290 0.83 HTR2C (0.46) ALDH1A1HTR2AHTR2CHTR2BMEN1
SCHEMBL4721571 0.83 HTR2C (0.46) ALDH1A1HTR2AHTR2CHTR2BMEN1
SCHEMBL4764168 0.82 HTR1D (0.47) ALDH1A1KDM4EHTR2CHTR2BHTR1D
SCHEMBL3174801 0.81 HTR2C (0.45) HTR2AHTR2CHTR2BSMN1; SMN2LMNA
SCHEMBL6387103 0.79 ADRA2A (0.44) HTR2AHTR2CHTR2BHTR1DSMN1; SMN2
SCHEMBL3165666 0.78 HTR2C (0.47) HTR2AHTR2CHTR2BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 ALDH1A1 622/4885KDM4E 2584/4885HTR2A 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.